Currently, many clinical practice guidelines, including the consensus guideline of the American Diabetes Association and the European Association for the Study of Diabetes, recommend glucagon-like peptide-1 receptor agonist (GLP-1RA) as the first-line injectable agent ahead of basal insulin for most patients with T2DM ( So far, two different products containing fixed-ratio combinations (FRCs) of basal insulin and GLP-1RA were approved by the US Food and Drug Administration and European Medicines Agency: IGlarLixi, which is a combo of insulin glargine and lixisenatide, and IDegLira, which is a combo of insulin degludec and liraglutide ( Based on these backgrounds, this study aimed to evaluate the overall effect of adding basal insulin on persisting GLP-1RA treatment
Food and Drug Administration-approved (FDA-approved) for the treatment of type 2 diabetes and has an additional indication for reducing the risk of major cardiovascular events, such as heart attack or stroke in individuals with type 2 diabetes and cardiovascular disease
Robert Kushner: All of the above you just said
The bile acid TUDCA and neurodegenerative disorders: an overview
The Mochi Health Lawsuit, Explained Simply This is one of the most searched topics related to Mochi Health, so lets walk through it carefully and factually
doi:10.1007/s00018-005-5163-7
